Hospira agrees $145 million acquisition with Javelin Pharmaceuticals
This article was originally published in Scrip
Executive Summary
Hospira has agreed a deal to buy Javelin Pharmaceuticals for $145 million, or $2.20 per share, in cash to broaden its portfolio of pain management offerings and take advantage of synergies between Javelin's main product candidate Dyloject (diclofenac injection) and Hospira's Precedex (dexmedetomidine injection).